GCTK Quote, Financials, Valuation and Earnings

Lifeward has a net margin of -- compared to GlucoTrack's net margin of -96.03%. GlucoTrack's return on equity of -- beat Lifeward's return on equity of -92.59%.

GlucoTrack has a consensus price target of --, signalling downside risk potential of --. On the other hand Lifeward has an analysts' consensus of $8.67 which suggests that it could grow by 1071.17%. Given that Lifeward has higher upside potential than GlucoTrack, analysts believe Lifeward is more attractive than GlucoTrack.

GlucoTrack has a beta of -0.236, which suggesting that the stock is 123.622% less volatile than S&P 500. In comparison Lifeward has a beta of 0.016, suggesting its less volatile than the S&P 500 by 98.425%.

GlucoTrack has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lifeward offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GlucoTrack pays -- of its earnings as a dividend. Lifeward pays out -- of its earnings as a dividend.

GlucoTrack quarterly revenues are --, which are smaller than Lifeward quarterly revenues of $5M. GlucoTrack's net income of -$6.8M is lower than Lifeward's net income of -$4.8M. Notably, GlucoTrack's price-to-earnings ratio is -- while Lifeward's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GlucoTrack is 6.23x versus 0.27x for Lifeward. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics has a net margin of -- compared to GlucoTrack's net margin of --. GlucoTrack's return on equity of -- beat Plus Therapeutics's return on equity of --.

GlucoTrack has a consensus price target of --, signalling downside risk potential of --. On the other hand Plus Therapeutics has an analysts' consensus of $9.17 which suggests that it could grow by 2729.22%. Given that Plus Therapeutics has higher upside potential than GlucoTrack, analysts believe Plus Therapeutics is more attractive than GlucoTrack.

GlucoTrack has a beta of -0.236, which suggesting that the stock is 123.622% less volatile than S&P 500. In comparison Plus Therapeutics has a beta of 0.693, suggesting its less volatile than the S&P 500 by 30.722%.

GlucoTrack has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GlucoTrack pays -- of its earnings as a dividend. Plus Therapeutics pays out -- of its earnings as a dividend.

GlucoTrack quarterly revenues are --, which are smaller than Plus Therapeutics quarterly revenues of --. GlucoTrack's net income of -$6.8M is higher than Plus Therapeutics's net income of -$17.4M. Notably, GlucoTrack's price-to-earnings ratio is -- while Plus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GlucoTrack is 6.23x versus 0.53x for Plus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vicarious Surgical has a net margin of -- compared to GlucoTrack's net margin of --. GlucoTrack's return on equity of -- beat Vicarious Surgical's return on equity of --.

GlucoTrack has a consensus price target of --, signalling downside risk potential of --. On the other hand Vicarious Surgical has an analysts' consensus of $10.75 which suggests that it could fall by -5.87%. Given that Vicarious Surgical has higher upside potential than GlucoTrack, analysts believe Vicarious Surgical is more attractive than GlucoTrack.

GlucoTrack has a beta of -0.236, which suggesting that the stock is 123.622% less volatile than S&P 500. In comparison Vicarious Surgical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

GlucoTrack has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vicarious Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GlucoTrack pays -- of its earnings as a dividend. Vicarious Surgical pays out -- of its earnings as a dividend.

GlucoTrack quarterly revenues are --, which are smaller than Vicarious Surgical quarterly revenues of --. GlucoTrack's net income of -$6.8M is higher than Vicarious Surgical's net income of -$15.4M. Notably, GlucoTrack's price-to-earnings ratio is -- while Vicarious Surgical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GlucoTrack is 6.23x versus -- for Vicarious Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -- compared to GlucoTrack's net margin of 0.18%. GlucoTrack's return on equity of -- beat Xtant Medical Holdings's return on equity of -26.62%.

GlucoTrack has a consensus price target of --, signalling downside risk potential of --. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 201.72%. Given that Xtant Medical Holdings has higher upside potential than GlucoTrack, analysts believe Xtant Medical Holdings is more attractive than GlucoTrack.

GlucoTrack has a beta of -0.236, which suggesting that the stock is 123.622% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.139, suggesting its less volatile than the S&P 500 by 113.918%.

GlucoTrack has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GlucoTrack pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

GlucoTrack quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $32.9M. GlucoTrack's net income of -$6.8M is lower than Xtant Medical Holdings's net income of $58K. Notably, GlucoTrack's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GlucoTrack is 6.23x versus 0.65x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.